Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Amgen Inc. (AMGN). You can receive reports or configure the research engine for yourself.
Report On:
Amgen Inc. (AMGN)
HEALTHCARE - Drugs - Biotechnology
Generated: Thursday September 15, 2011 04:03 AM
|
|
||||||||||||||||||
Quotes About Amgen Inc.
-
FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
We welcome Mike to FibroGen and are pleased to have his expertise and experience in technical development, particularly as we prepare for phase 3 development activities in our anemia program,"
- Thomas B. Neff -
Pfizer Poised to Introduce Blockbuster Arthritis Pill
the new drug may bring in more than $2.6 billion a year,"
- Catherine Arnold -
Circadian Technologies appoints Dr Ian Leitch to clinical trials management team
As we move into the clinical development phase of our development in oncology and eye disease it is critical that we have the best people managing this activity. "
- Robert Klupacs -
Pfizer's Arthritis Pill Matches Abbott's Shot in Final Studies
Pfizer believes the risk-benefit profile supports regulatory submission for both the 5 and 10 mg dose," -
Lourie Zak, Former Amgen Finance Executive, Joins PBS Biotech, Inc. as Chief Financial Officer (BIZ)
Lourie is a great addition to the PBS Biotech executive team and will be a driver in managing our financial controls, providing financial leadership and decision support, and in securing capital for our growth,"
- Brian Lee
Latest Company Intelligence
-
IBM Takes Another Step Toward HAL
Wall St. Cheat Sheet | Sep 13,'11
WellPoint Inc. , ( NYSE:WLP ) which provides health care to over 34.2 million members, will use IBM's ( NYSE:IBM ) super computer Watson to help diagnose medical problems and authorize appropriate treatment . Watson's lightning speed and vast health care database is starting to resemble HAL from the science fiction movie 2001: A Modern Space Odyssey . -
Sermo/Fierce Pharma Survey of Oncologists Named Amgen and Novartis As Being The Top Contributing Drug Companies
The Medical Quack | Sep 9,'11
This is another in the series of contributions of surveys and polls to provide actual MD comments and results on which drugs companies they feel are the biggest contributors to cancer with the best outcomes. Amgen and Novartis are the top and there were others as well. The actual report goes into more detail and you can read the entire report here . Roche was right in there as well -
Top Analyst Upgrades & Downgrades (AMGN, ARIA, BIIB, CELG, LFC, CSCO, DRI, FIO, GPN, HUM, LEN, MSI, TLB, TZOO)
24/7 Wall St | Sep 8,'11
These are some of this Thursday's top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Outperform at BMO. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) Started as Outperform at BMO. Biogen Idec Inc. (NASDAQ: BIIB) Started as Underperform at BMO. Celgene Corporation (NASDAQ: CELG) Started as -
Pfizer's Arthritis Pill Matches Abbott's Shot in Final Studies
Bloomberg Businessweek | Sep 8,'11
Sept. 8 (Bloomberg) -- Pfizer Inc.'s experimental pill for rheumatoid arthritis was as effective as Humira from Abbott Laboratories and showed no new side effects in study results the company plans to submit for U.S. approval this year. Nine study summaries were released today and will be presented at the American College of Rheumatology conference in Chicago in November. In one -
Amgen Biotech Diversity: Pipeline For The Future, Stock Stability For Income
Seeking Alpha | Sep 5,'11
Amgen ( AMGN ) is a biotechnology company based in California. Amgen is the world's largest independent biotech firm. It currently has 12 drugs that have been FDA approved to treat 17 conditions. It approved drugs to treat the following conditions: anemia, arthritis, oral mucositis, rheumatoid arthritis, neutropenia, colon cancer, secondary hyperparathyroidism, immune -
Cancer-fighting virus shown to target tumors alone
AlertNet | Aug 31,'11
* Small trial shows virus hits cancer, spares normal cells * Mid-stage trial in liver cancer patients under way * Another big step in 'customizing' viruses to target tumors LOS ANGELES, Aug 31 (Reuters) - Researchers have shown for the first time that a single intravenous infusion of a genetically engineered virus can home in on cancer, killing tumor cells in patients without harming
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
